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Magnetic resonance spectroscopy (MRS) from voxels placed in the left anterior cingulate
cortex (ACC) was measured from 14 boys with Autism Spectrum Disorder (ASD) and 24
gender and age-matched typically developing (TD) control group. Our main aims were
to compare the concentration of γ-aminobutyric acid (GABA) between the two groups,
and to investigate the relationship between brain metabolites and autism symptom
severity in the ASD group. We did find a significant negative correlation in the ASD group
between Autism Spectrum Screening Questionnaire (ASSQ) and GABA+/Cr, which may
imply that severity of symptoms in ASD is associated with differences in the level of
GABA in the brain, supporting the excitatory/inhibitory (E/I) imbalance theory. However
we did not find a significant difference between the two groups in GABA levels.
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Introduction
Autism Spectrum Disorder (ASD) is a pervasive developmental disorder characterized
by deficits in social communication and social interaction and by restricted, repetitive
patterns of behavior, interests or activities. Symptoms must be present in an early
developmental period (before 3 years of age), but they do not necessarily become
Abbreviations: ASD, Autism Spectrum Disorder; MRS, Magnetic Resonance Spectroscopy; ppm, Parts per million;
NAA, N-acetylaspartate; Glu, Glutamate; Gln, Glutamine; MI, Myo-inositol; Cho, Choline; Cr, Creatine; PCr,
Phosphocreatine; GABA, Gamma-aminobutyric acid; MM, Macromolecules; GABA+, GABA including associated
MM; E/I, Excitatory/inhibitory; TD, Typically developing; SIB, Unaffected siblings; Glx, Glutamate and glutamine;
ACC,Anterior cingulate cortex; ASSQ,Autism SpectrumScreeningQuestionnaire;WASI,Wechsler Abbreviated Scale
of Intelligence; DAWBA, Development and Well-Being Assessment; SDQ, Strengths and Difficulties Questionnaire;
ADHD, Attention deficit/hyperactivity disorder; ADD, Oppositional defiant disorder; TR, Repetition time; TE, Echo
time; CRLB, Cramér-Rao lower bounds; CSF, Cerebro spinalfluid; Gray, Gray matter; White, White matter.
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fully manifest until social demands exceed limited capacities
(American Psychiatric Association, 2013). The estimated
prevalence of ASD in the Norwegian population ranges
from 0.44 to 0.87% (Heiervang et al., 2007; Posserud
et al., 2010; Surén et al., 2012) with four times as many
boys as girls diagnosed with the disorder (Baron-Cohen
et al., 2009b). Autism is now called ‘‘spectrum disorder’’
because of the recognition that its manifestation and severity
displays great heterogeneity depending on intellectual ability,
associated symptoms, possible etiology and developmental
level (American Psychiatric Association, 2013). Although
there is clearly a genetic basis to ASD, the majority of cases
have unknown causes (Abrahams and Geschwind, 2008;
Geschwind, 2008). It is, moreover, now widely accepted that
ASD is a neurobiological disorder, but specific biological
markers are yet to be established (McPheeters et al., 2011;
Warren et al., 2011).
Magnetic resonance spectroscopy (MRS) has made it possible
to study the concentration of biochemical substances in the
healthy and diseased brain (Soares and Law, 2009). By measuring
from a volume element (MRS voxel) in specific regions of
interest, metabolite concentrations can be estimated due to
differences in spectral resonances from the main water peak.
Using the PRESS (Point RESolved Spectroscopy) single-voxel
spectroscopy sequence (Bottomley, 1987), metabolites such as
N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln),
myo-inositol (MI), choline (Cho) and creatine (Cr), can be
measured. Unfortunately, other important metabolites such
as γ-aminobutyric acid (GABA) are not detectable using
conventional MRS, due to spectral overlap with more abundant
metabolites at 3.02 parts per million (ppm). One way to
measure the concentration of GABA is with a spectral editing
technique such as BASING (Star-Lack et al., 1997) or MEGA-
PRESS (Mescher et al., 1998). A pair of frequency selective
inversion pulses within a standard PRESS sequence allows
discrimination between overlapping coupled and uncoupled
spins. For GABA editing the editing pulses are applied to
the C-3 protons of GABA at 1.9 ppm. Due to the spin-
spin coupling the C-4 protons of GABA at 3.02 ppm are
affected while other metabolite peaks like the strong Cr
peak remains unaffected. Subtracting the spectrum from a
second acquisition scheme without these editing pulses (or
applied symmetric to the water signal, e.g., at 7.5 ppm),
will give a difference spectrum without the strong singlet
signal from Cr, allowing quantification of the GABA peak
at 3.02 ppm. As these GABA protons are also coupled
to macromolecules (MM) at 1.7 ppm this peak consists
of GABA and an unknown contribution of MM signal
and is therefore named GABA+ (GABA+ MM). This is
in line with current best practices (Mullins et al., 2014)
and hence compatible with the bulk of existing research
including studies on ASD (Gaetz et al., 2014; Rojas et al.,
2014).
Glutamate is the major excitatory neurotransmitter and
GABA is the major inhibitory neurotransmitter in the brain,
and probably all areas receive input from both of these
neurotransmitters. The balanced interaction between excitatory
and inhibitory neurotransmission is tightly regulated (Carlson,
2001) and is essential for controlling cognition, learning,
memory and emotional behaviors. Several studies support
the idea that imbalance in the glutamate/GABAergic system
could be present in a wide range of disorders with quite
different clinical appearances, like Downs syndrome, epilepsy,
neurofibromatosis and schizophrenia (Ramamoorthi and Lin,
2011).
Lately increasing evidence have emerged suggesting that also
ASD may be associated with abnormalities in the glutamate
and GABA system including neurotransmitters, receptors and
enzymes (Pizzarelli and Cherubini, 2011) often referred to as
the excitatory/inhibitory (E/I) imbalance theory. It has been
hypothesized that the E/I ratio in the cortex is unusually high,
either due to increased glutamate—or because of decreased
GABAergic signaling (Rubenstein and Merzenich, 2003). An
E/I imbalance might explain the typical ASD symptom of
hypersensitivity to sensory stimuli, including aversion to loud
noises, tactile stimulation, and bright lights (Kanner, 1943;
Baron-Cohen et al., 2009a).
GABAergic dysfunction in ASD has been proposed in animal
models (Gogolla et al., 2009; Chao et al., 2010), post mortem
studies and in vivo human studies; see overview Coghlan et al.
(2012). The E/I imbalance hypothesis is also consistent with
the observation that rates of epilepsy are higher in the autism
population than in the general population (Gillberg and Billstedt,
2000). Another important finding is that gamma oscillations
are reduced in ASD patients (Grice et al., 2001; Brown et al.,
2005; Wilson et al., 2007). Gamma oscillations a re generated
by GABAergic neurons (Pizzarelli and Cherubini, 2011), and
are involved in sensory binding and higher cognitive functions
(Lisman and Idiart, 1995).
When starting this study, there was, to our knowledge, only
one previous study using theMEGA-PRESS sequence to measure
the concentration of GABA in the brain of children with ASD
compared with normal controls, and our study was designed to
further explore the E/I theory. Harada et al. (2011b) reported
significantly lower GABA+/NAA and GABA+/Glu ratio in a
voxel placed in the left frontal lobe in a population of children
with ASD aged 2–11 years compared to a typically developing
(TD) control group (n = ASD/TD: 12/10). Since then two
more studies have been published. Gaetz et al. (2014) had three
different spatially localized voxels; in the left motor cortex (n =
17/15), left auditory cortex (n = 15/11) and the left visual cortex
(n = 8/10), respectively. They found that the GABA/Cr ratio
was significantly reduced in the motor and auditory cortex, but
not significantly different in the visual areas in ASD children
aged 11.5 ± 2.7 years compared to TD. The last study, Rojas
et al. (2014), found reduced GABA/Cr ratio in a voxel placed
in the left auditory cortex in children with ASD aged 14 ±
5 years compared with their unaffected siblings (SIB) aged
12 ± 6 years, and TD aged 12 ± 5 years (n = ASD/SIB/TD:
17/14/17).
To explore the excitatory/inhibitory imbalance theory
our aim was to study children aged 6–13 with ASD without
sedation using both PRESS and MEGA-PRESS sequence.
Since studies in healthy individuals have shown significantly
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higher concentrations of GABA, Glutamate + Glutamine
(Glx), and Glu in males compared to females (O’Gorman
et al., 2011), only boys were included in the current
study.
MRS measured metabolite concentrations are normally
presented as ratios of water, total Cr, NAA or in the case of
GABA, Glx have also been used. The concentrations obtained
from MEGA-PRESS use water as an internal concentration
reference, meaning that all our GABA+ data are scaled to water.
We have chosen to display our results as GABA+ and GABA+/
Cr since there are reports from previous studies that there exist
group differences between ASD and TD in both NAA (Aoki
et al., 2012) and Glx (Horder et al., 2013). Gaetz et al. (2014)
and Rojas et al. (2014) also used GABA+/Cr to present their
results.
We assessed GABA and other brain metabolite levels from a
voxel in the left anterior cingulate cortex (ACC) using a voxel size
of 30× 30× 30 mm3 (27 ml) see Figure 1.
Although closer to the midline of the brain, this voxel
placement partly overlaps the voxel placement in the Harada
et al. (2011b) study. This was one of the few locations in the
frontal lobe where it was possible to fit the relatively large voxel
without including bone or cerebrospinal fluid (CSF) in these
children. The dorsal portion of the ACC has been shown to be
involved in higher cognition and intellectual functioning (Bush
et al., 2000), and other studies have in particular implicated the
left ACC in patients with mental disorders (Minzenberg et al.,
2009).
All participants were assessed using the Autism Spectrum
Screening Questionnaire (ASSQ) and parts of the Wechsler
Abbreviated Scale of Intelligence (WASI) as variations
in both autism severity and intellectual level may have
an impact on metabolite levels. To explore the possible
relationship between autism severity and GABA, our GABA+
measurements were correlated with the ASSQ scores (Ehlers
et al., 1999). In accordance with the E/I imbalance hypothesis,
we hypothesized that we would find a lower concentration of
GABA+ and GABA+/Cr ratio in the ASD group compared
with the TD group, and that the GABA+ concentration and
the GABA+/Cr ratio would correlate negatively with the
ASSQ score.
Methods
Participants
The boys in the ASD group were recruited through parents
groups, patient organizations, newspaper advertisements, from
the educational and psychological counseling service in the
municipality, and from patients receiving care at a private
clinic. The boys in the TD group were recruited from the
National Registry. The boys in the ASD group had been
independently assessed and diagnosed by child psychiatric
outpatient clinical specialists in Norway. Documentation of
the clinical assessment leading to an ASD diagnosis was
requested and reviewed by a clinical ASD expert (co-author
M.P.) for all ASD boys to confirm the ASD diagnosis and
ensure that they fulfilled the diagnosis also according to the
DSM-5 criteria (American Psychiatric Association, 2013). In
addition the parents/legal representatives in the TD group
were interviewed using the ASD section of the structured
interview Development and Well- Being Assessment (DAWBA)
to exclude presence of ASD in the TD group (Goodman
et al., 2000). Height and weight of all participants were
measured prior to imaging and the parents filled out a screening
questionnaire for mental health including the Strengths and
Difficulties Questionnaire (SDQ; Goodman, 1997), the ASSQ
(Ehlers et al., 1999), items on learning problems, obsessive
compulsive disorders, tics and the DSM-IV criteria for attention
deficit/hyperactivity disorder (ADHD) and oppositional defiant
disorder (ODD), to rule out presence of neuropsychiatric
conditions in TD children (Heiervang et al., 2007; Posserud
et al., 2009). The ASSQ has been thoroughly validated as
measure of ASD and was furthermore used as measure of
autism severity (Ehlers et al., 1999; Posserud et al., 2009).
FIGURE 1 | Placement of magnetic resonance spectroscopy (MRS) voxel in the left anterior cingulate cortex (ACC). This figure shows the typical
placement of the 3 × 3 × 3 cm MRS voxel in the left ACC.
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The two sub-tests Vocabulary and Matrices Reasoning of the
WASI as tests of general intellectual capacity and cognitive
skills (Wechsler, 1999) were assessed in both groups by
trained psychology students. In addition, information regarding
ethnicity, other illnesses, medication, and supplements and
diets were noted. Exclusion criteria in both groups were
braces (for the MR investigation), genetic abnormalities and
prematurity (<36 weeks). Epilepsy, autistic traits and other
neuropsychiatric disorders were exclusion criteria in the TD
group.
We included boys with epilepsy in our ASD group since it
is estimated that 30% of ASD patients also have epilepsy, and
subclinical epileptiform activity is recorded on scalp EEG in
up to 85% of children with ASD (Gillberg and Billstedt, 2000;
Yasuhara, 2010). By excluding children with epilepsy we found
that our ASD group would not be representative of children with
ASD in general.
In the ASD group, 20 boys were initially recruited from which
14 (mean age 10.2 ± 1.9 years), completed the MRI examination
with acceptable PRESS andMEGA-PRESS data as per our quality
criteria described in the later ‘‘MRS data analysis’’ section. Three
boys in the ASD group did not complete the WASI tests but they
were nevertheless included for MRS analyses.
TD boys were recruited as control participants. In the TD
group, 30 boys were initially recruited. Three of them were
excluded prior to the data analyses; one had a large arachnoid
cyst, and two scored above the 90-percentile relative to the
population norm from the Bergen Child Study (Heiervang et al.,
2007) on the screening questionnaires. Three TD boys did not
complete the MR examination. This resulted in a total of 24 boys,
mean age 10.2± 1.8 years in the TD groupwith acceptable PRESS
data, while MEGA-PRESS data was acceptable in 21.
Ethical Approval
The study was approved by the Regional Committee for Medical
and Health Research Ethics, and was conducted in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from the children’s parents/legal representatives.
Magnetic Resonance Imaging (MRI)
Brain MRI scans were acquired using a 3T GE Signa HDxt MR
scanner (GE, Milwaukee, USA) equipped with an 8-channel head
coil. The followingMR protocol was used for acquisition of brain
metabolites:
1. PRESS sequence with TE = 35 ms and TR = 1500 ms, 128
averages giving a total acquisition time (TA) of 3:48 min.
2. MEGA-PRESS with TE = 68 ms and TR = 1500 ms, 128
averages each for edited and unedited parts giving TA =
7 min. The somewhat low number of averages was necessary
to minimize scan time with a difficult subject demographic.
GABA-editing was achieved with 16 ms 180◦ Gaussian
editing pulses applied at 1.9 ppm and 7.5 ppm with alternating
acquisition, giving the ‘‘edit-on’’ and ‘‘edit-off’’ spectra with
the GABA spectrum obtained by taking the difference between
the two acquisitions. Water reference lines were acquired
as a part of the acquisition both for PRESS and MEGA-
PRESS.
The MR scanning protocol also included a 3D T1 weighted
anatomical scan (number of slices = 192, slice thickness =
1.0 mm, repetition time (TR) = 7.8 ms, echo time (TE) =
2.95 ms, field of view = 260 × 260 mm2 flip angle = 14◦,
matrix = 256 × 256) for anatomical imaging and positioning of
the MRS voxel. The T1-images from the SPGR sequence were
reformatted from sagittal to oblique axial slice direction with
slices positioned parallel to the line connecting the lowest edge
of the splenium and the rostrum sections of the corpus callosum.
The ACC voxel was then positioned on the left side near the
midline of the brain between the genu and middle section of
the corpus callosum with the lower voxel edge tangential with
the upper border of corpus callosum, to avoid CSF, bone and fat
contamination.
MRS Data Analysis
Water-scaled metabolite concentrations from the PRESS and
the MEGA-PRESS data were analyzed with the LCModel
analysis software version 6.3-1H (Provencher, 1993). A simulated
MEGA-PRESS basis set and constrained baseline were used
in the fit. For valid PRESS results the standard deviation was
required to be %SD < 20% (Cramér-Rao lower bounds/CRLB)
and %SD < 20% for the GABA values in the MEGA-PRESS data
(Tables 1, 2).
The curve fitting of the GABA peak at 3.02 ppm was
visually inspected in each individual. Additional validation
was performed using an in-house quality-assurance script
implemented in Python.1 This script validates individual spectra
against a typical (group average) spectrum for the region and
identifies any aberrations in shape of the spectra or features
in the residuals—as would result from artifacts or poor fitting.
It additionally checks quantitative metrics such as linewidth,
signal-to-noise, and CRLB across the fit. This process is
intended to guide and to complement regular visual inspection
(Figure 2).
Statistics
Demographic data, ASSQ, intellectual ability (WASI) and MRS
data were analyzed using SPSS (version 12.01) (IBM Corp.
USA) statistical analysis software package. MRS measurements
were non-normally distributed, even after log transformation,
and results were thus analyzed using the non-parametric Mann
Whitney U-test and Skipped Pearson and Spearman correlation
(Pernet et al., 2013) with the level of significance being p ≤ 0.05.
The GABA+/Cr ratio was normally distributed and the Students
t-test was therefore applied.
Quantifying Tissue Composition
GABA tissue concentration has been demonstrated to differ
between gray matter (GM) and white matter (WM; Petroff
et al., 1988). The segmentation of GM, WM and CSF within
the MRS voxel was carried out on the 3D-SPGR images.
Segmentation was performed using in-house scripts based on
1https://www.python.org
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TABLE 1 | SNR (signal to noise ratio) and linewidth expressed as FWHM
(Full width at half maximum) in ppm.
MEGA-PRESS ASD (n = 14) TD (n = 21) P-value
SNR 20.7 ± 4.1/20.5 19.9 ± 2.6/20.0 0.41
FWHM 0.044 ± 0.014/0.038 0.038 ± 0.010/0.033 0.26
PRESS ASD (n = 14) TD (n = 24) P-value
SNR 26.6 ± 5.3/28.0 28.7 ± 2.6/29.0 0.39
FWHM 0.047 ± 0.015/0.046 0.044 ± 0.009/0.048 0.82
TABLE 2 | % CRLB (Cramer-Rao Lower Bound) for selected metabolites.
MEGA-PRESS ASD (n = 14) TD (n = 21) P-value
GABA+ 0.07 ± 0.015/0.07 0.07 ± 0.011/0.06 0.70
PRESS ASD (n = 14) TD (n = 24) P-value
Cr 0.02 ± 0.006/0.02 0.02 ± 0.004/0.02 0.94
NAA 0.02 ± 0.005/0.02 0.02 ± 0.003/0.02 0.25
MI 0.04 ± 0.007/0.03 0.03 ± 0.006/0.03 0.75
Cho 0.02 ± 0.004/0.02 0.02 ± 0.002/0.02 0.39
Glx 0.04 ± 0.008/0.04 0.04 ± 0.006/0.04 0.99
SPM’s unified segmentation and normalization functionality.2
The same software was also used to calculate total GM and WM
volume and total brain volume.
Results
Medication
Five of the 14 boys in the ASD group used
psychotropic medication; one was medicated with
lamotrigine (antiepilepticum), two with metylphenidate
(ADHD medication), one with aripriprazol (antipsychotic
medication) and one with metylphenidate and levetiracetam
(antiepilepticum). A further two used melatonin. None of the
participants in the TD group were on medication.
Autism Severity
All TD boys scored below the screening cut-off for ASD on the
ASSQ, and all the ASD boys scored higher than all the TD boys
(mean ASSQ score 23.5 in the ASD group vs. 1.5 in the TD group,
p< 0.001).
WASI Two Subtest Format
The results for the WASI total score and scores for the two
subtests are shown in Table 3.
As can be seen in Table 1, the ASD group scored below the TD
group on all three WASI variables. The difference is significant
for the Vocabulary scores, and approaches significance for the
Matrix Reasoning scores (p = 0.07). However, the total score
including both subtests was not significantly different between
groups and both groups were within normal range of intellectual
capacity.
2http://www.fil.ion.ucl.ac.uk/spm/software/spm8/
MRS Results
Below is a summary of findings for both the PRESS and
MEGA-PRESS sequences in the two groups. Table 4 there were
no statistically significant differences between the two groups
(ASD/TD) in GABA+ and GABA+/Cr levels. For comparison
with previous studies, analyses were also performed with
GABA+/Glx and GABA+/NAA, but no statistically significant
differences between the two groups were found. See also scatter
plots for the distribution of GABA+ and GABA+/Cr in the two
groups (Figure 3).
There was a statistically significant negative correlation
between the ASSQ score and the GABA+/Cr concentration in
the ASD group, (Figure 4). The significant negative correlation
between GABA+ and ASSQ when using the Pearson correlation
coefficient did not hold when the skipped Pearson and skipped
Spearman test was applied.
The correlations did not survive correcting for multiple
comparisons due to the relative low number of participants.
Controlling for WASI did not change the strength or direction
of the correlation between ASSQ and GABA, but the statistical
significance was lost.
ASSQ is a questionnaire instrument applied to measure
autism severity with values above the cut off set at 17 indicating
ASD. The TD group all had ASSQ scores below 5. Still,
correlation analyses were performed between the ASSQ score and
GABA+ and the ratios and none of themwere statistic significant.
Tissue Segmentation
There were no group differences in total brain volumes and
segmented tissue volumes in the MRS voxel (Table 5). As no
systematic differences in tissue composition were observed, these
estimates were not considered further in the statistical analysis.
Discussion
In our correlation analyses we found significant negative
correlations in the ASD group between ASSQ score and
GABA+/Cr ratio, indicating that lower GABA+/Cr ratio is
associated with increasing autism severity.
This is the first paper, to our knowledge, that has examined
autism symptom severity and correlated this with metabolite
concentration measured from MRS using a MEGA-PRESS
sequence. However, our study supports the MEG-study by
Cornew et al. (2012) where they did find an association between
oscillatory anomalies, which suggest E/I imbalance, and autism
symptom severity. The participants in the Cornew study were 50
children, 27 with ASD and 23 age-matched controls, aged 6–15
years.
Our study did not reveal any group-level differences between
the ASD and the TD group regarding the concentration of
GABA+ and GABA+/Cr. These results do not fully support
all the results from the three previous studies (Harada et al.,
2011b; Gaetz et al., 2014; Rojas et al., 2014) that have applied
MRSMEGA-PRESS to compare brain GABA+ concentrations in
children with ASD.
Harada et al. (2011b) found significantly lower GABA+/NAA
and GABA+/Glu ratio in the ASD group, with a voxel placed in
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FIGURE 2 | Examples of a good and a poor quality MEGA-PRESS
spectrum. (A) The MEGA-PRESS spectrum shows a clearly visible GABA+
peak at 3.0 ppm. The difference between the data and the fitted curve, the
residual, is small indicating a good fit. (B) The MEGA-PRESS spectrum is noisy
with no clear GABA+ peak at 3.0 ppm. The residual is also large indicating a
poor fit.
TABLE 3 | WASI IQ scores.
ASD (n = 11) TD (n = 24) P-value
WASI, total score 97.6 ± 19.6/95.0 108.3 ± 14.3/107.0 0.11
Raw score Vocabulary 30.8 ± 15.4/34.0 40.4 ± 9.4/41.5 0.04
Raw score Matrix
Reasoning 19.7 ± 8.3/23.0 25.8 ± 9.3/26.5 0.07
Data are presented as mean ± standard deviation/median value.
the left frontal lobe, partly overlapping with our voxel placement
in the left ACC. Gaetz et al. (2014) found a significantly reduced
GABA+/Cr ratio in the ASD group in voxels placed in the
left motor and auditory cortex, while Rojas reported reduced
GABA+/Cr ratio in children with ASD and their unaffected
siblings compared to TD controls in a voxel placed in the left
auditory cortex (Rojas et al., 2014).
TABLE 4 | The summarized results for the quantization of relevant
metabolites from the MEGA-PRESS and PRESS sequences.
MEGA-PRESS ASD (n = 14) TD (n = 21) P-value
GABA+ 2.49 ± 0.40/2.53 2.66 ± 0.45/2.56 0.41
GABA+/Cr* 0.42 ± 0.066/0.42 0.44 ± 0.074/0.43 0.30
PRESS ASD (n = 14) TD (n = 24) P-value
Cr 6.01 ± 0.54/6.00 6.08 ± 0.39/6.05 0.71
NAA 8.61 ± 0.60/8.66 8.99 ± 0.73/9.08 0.10
MI 5.18 ± 0.87/5.08 4.98 ± 0.54/4.95 0.69
Cho 2.17 ± 0.21/2.16 2.19 ± 0.21/2.18 0.80
Glx 15.2 ± 1.58/15.00 15.49 ± 1.17/15.48 0.35
The concentrations obtained from the MEGA-PRESS experiment use water as an
internal concentration reference. *Cr from PRESS. Data are presented as mean ±
standard deviation/median. Values for metabolites are in Institutional Units.
An obvious difference between the three studies is that
the voxel placements in our study differed from the others.
The ACC region was chosen for voxel placement since
the area is implicated in the pathophysiology of ASD due
to its crucial role in social cognitive processes (Devinsky
et al., 1995; Bush et al., 2000; Amodio and Frith, 2006).
The ACC region is also known to be involved/affected in
patients with psychiatric disorder including schizophrenia,
obsessive–compulsive disorder, depression, post-traumatic stress
disorder and ASD (Benes, 1993; Rauch et al., 1994; Devinsky
et al., 1995; DeVito et al., 2007; Minzenberg et al., 2009).
Several recent studies implicate the ACC region in ASD,
and also connected it to imbalances in GABA/Glu. For
example, Naaijen et al. (2015) found aberrant fronto-striatal
glutamatergic levels, including the ACC in children with ASD.
Similarly, Cochran et al. (2015) found that glutamate-GABA
interaction and balance was disturbed in ASD subjects, and
that this correlated with social cognition measures. Finally,
Hall et al. (2015) used an auditory oddball task that requires
complex cognition, and measured both electrophysiology
responses and MRS glutamate levels from the ACC and
found a significant positive correlation between the two
indicating a specific connection between an index of glutamate
neurotransmitter function and frontal event-related potential.
Thus, the ACC region has been shown to be sensitive for subtle
changes in metabolite levels during social cognitive and rest
periods.
Both Harada et al. (2011b) and Gaetz et al. (2014) showed
that there might be regional differences as they found lower
concentration of GABA+ in ASD individuals in some areas of
the brain and with no group differences in other areas compared
to TD individuals. Further studies are needed to investigate the
role of voxel placements for GABA+ measurements.
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FIGURE 3 | Scatter plots showing the distribution of GABA+ ratios in the autism spectrum disorder (ASD) and typically developing (TD) groups.
(A) GABA+; (B) GABA+/Cr; (C) GABA+/NAA; and (D) GABA+/Glx.
Another possibility is that there are subgroups in the ASD
population where differences in GABA+ or the metabolites used
in the GABA+ ratio exist, whichmay explain the heterogeneity in
the ASD phenotype. All four studies on ASD children, referred
to in this manuscript, including our study, had small sample
sizes. The subjects in the Harada paper had a wide age range
(Harada et al., 2011b), and there was no information whether the
included subjects were boys or girls, while both boys and girls
were included in the Gaetz et al. (2014) and Rojas et al. (2014)
paper. In addition the Gaetz paper lacked sufficient information
about the recruitment of TD. As pointed out earlier, gender may
be a significant factor in predicting GABA+ levels (Harada et al.,
2011a; O’Gorman et al., 2011), however other studies have not
shown this difference (Puts and Edden, 2012). We need more
knowledge on how age and gender influences GABA+ levels and
we cannot rule out that such group differences contribute to the
previous results.
A strength in our study is that we only included boys, and
there were no age differences between the two study groups.
Moreover, both groups had total mean IQ scores within normal
range. Thus we think our results are representative for boys in
this age group. The discrepancy between the groups in IQ with
lower verbal IQ scores in the ASD group was expected, since it
reflects a clinical characteristic of children with ASD (Mayes and
Calhoun, 2003).
Controlling for WASI did not change the strength or
direction of the correlation between ASSQ and GABA+,
indicating that WASI was not a confounder in our analyses.
Thus the variation in performance on WASI (IQ) seems
secondary compared to a composite measure of ASD symptoms
(ASSQ) to describe the variation GABA+/Cr ratio in the ACC.
The lower GABA values were associated with more severe
ASD symptoms. More in depth neuropsychiatric tests were
not included in this study, therefore it is not possible to
evaluate performance of functions typically associated with
the ACC region such as executive control, theory of mind
etc. While there may be some association between regional
GABA+ content and neuropsychological performance, further
studies are needed to explore these possible confounding
factors.
Use of medication differed between the groups; 5 of 14
boys in the ASD group used psychotropic medication and an
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FIGURE 4 | Skipped Pearson and Spearman correlations with a 95% confidence interval (CI). The figures also include Bootstrapped Pearson and
Bootstrapped Spearmans plots. (A) ASSQ vs. GABA+/Cr; (B) ASSQ vs. GABA+.
additional two used melatonin, vs. no medications in the TD
group. GABA inhibition is a well-known target for therapeutic
anticonvulsant treatment, but neither of the two antiepileptic
drugs lamotrigine and levetiracetam have GABA enhancement
as their main effect (Olsen and Avoli, 1997). An MRS study
by Kuzniecky et al. (2002) showed a 25% increase in GABA
concentration on five healthy volunteers administered with long-
term dosing of lamotriginemeasured from a voxel in the occipital
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TABLE 5 | Results for the total brain volume ratios measured by tissue
segmentation, and results from tissue segmentation in the MRS voxel.
ASD TD P-value
Brain volume Gray 855 ± 72/865 882 ± 75/874 0.50
Brain volume White 405 ± 37/406 418 ± 42/422 0.38
Brain volume total 1261 ± 99/1277 1300 ± 112/1301 0.46
Voxel CSF 5.5 ± 4.7/4.3 3.4 ± 2.6/2.5 0.20
Voxel Gray 44.7 ± 5.6/45.2 45.2 ± 5.2/43.9 0.89
Voxel White 48.7 ± 10.3/53.0 51.3 ± 7.2/53.4 0.39
Data are presented as mean ± standard deviation/median. All volumes are in ml.
lobe. The exact mechanism of levetiracetam in treating epilepsy
is unknown, and in vivo studies of levetiracetam on whole mice
brain preparation haven not detected any differences on the
overall GABA and glutamate concentration (Sills et al., 1997).
All analyses were performed both with and without the two
boys using antiepileptic drug and it had no significant effect on
the results for the group level analyses.
Methylphenidate has a dopaminergic effect similar to
amphetamine and cocaine by blocking the dopamine and
noradrenaline transporters in pre-synapse, thus increasing the
availability of these neurotransmitters in the synaptic cleft.
GABA can modify the activity of dopaminergic neurons, and
psychostimulants (Pierce and Kalivas, 1997) may also influence
the activity of GABAergic neurons directly. One study on
female rats found that repeated treatment with methylphenidate
significantly increased the expression of GAD65 and GAD667
in the prefrontal cortex thus increasing vesicular GABA levels
(Freese et al., 2012). There is limited research available on
the effects of methylphenidate on GABA levels in humans;
therefore a possible impact on GABA levels cannot be
excluded.
An 18F-Fluoroflumazenil PET study on 17 patients with
schizophrenia found that aripiprazole administration resulted in
increased GABA transmission in the prefrontal cortex (Lee et al.,
2013).
Melatonin activates the benzodiazepine-GABAA receptor
complex with consequent enhancement of GABAergic activity
(Niles, 2006).
A common denominator of the four types of psychotropic
medication and melatonin is that they may all increase GABA+
levels, and they may thereby potentially mask an underlying
group difference in GABA+ level between the ASD and the
TD group. When comparing with the three other MEGA-
PRESS studies on children with ASD, we found no information
regarding epilepsy or usage of psychotropic medication in the
Harada et al. (2011b) paper. Gaetz et al. (2014) and Rojas
et al. (2014) excluded children with epilepsy from the ASD
group. In the Rojas et al. (2014) study five ASD children
used psychotropic medication, four SSRI and one an atypical
antipsychotic drug. In the Gaetz et al. (2014) study four
ASD children used psychotropic medication, two a SSRI,
one a ‘‘medication to treat mood disorder’’ and one atypical
antipsychotics. Regarding the effect of medication on GABA+/Cr
ratio, Rojas et al. (2008), Gaetz et al. (2014) and our own study are
comparable.
Most of the children in the Harada et al. (2011b) study were
sedated with triclofos sodium, a GABA agonist, which might
complicate the interpretation of their results. Reduced Glu and
increased GABA have been observed bilaterally in all cortical
regions examined following sedation with propofol (Zhang et al.,
2009), which is another GABA agonist. It may be that an effect of
sedation has influenced the MRS measurements and contributed
to their results.
Beyond any real underlying physiological variations, our
GABA+ measurements may also be affected by the different
MRI acquisition parameters used—in particular, the number of
averages. We chose to average over 128 pairs in order to keep
the scan time down and thereby minimize any errors due to head
movement. Lying completely still in the scanner is challenging
for children, and even more so for children with ASD. Both the
Harada et al. (2011b) and the Gaetz et al. (2014) paper used 128
averaged pairs in their MR protocols, while in the paper by Rojas
they averaged 256 pairs (Rojas et al., 2014), giving twice as many
spectral acquisitions and correspondingly improved signal-to-
noise, but also increasing the scan time significantly (to about
20 min with their TR of 2500 ms). A recent study from our group
(Craven abstract ISMRM 2014) suggests that an average of 256
pairs at TR = 1500 ms is more optimal for measuring GABA+
using MEGA-PRESS.
Applying the MEGA-PRESS GABA-editing MRS sequence
for measurement of GABA+ in the human brain has become
increasingly of interest during the last couple of years,
especially when evaluating neurochemical underpinnings of
psychiatric disorders. Even so, the most stable denominator for
normalized GABA+ measures, like basic sequence parameters
and specific method of spectral quantification, still remains
an active area of investigation. Thus, it is a possibility that
there exists a difference in GABA+ levels between groups,
but that we were not able to measure it. MR parameters,
like number of averages, and voxel placement are probably
more a factor than the MEGA-PRESS method itself, and with
further optimization a more subtle difference may become
apparent.
As mentioned in the introduction, ASD patients represent a
very heterogeneous group, probably reflecting variability within
the autism spectrum with different neurobiological substrates.
It is hardly likely that we will find one causal model for ASD.
Using different methods, e.g., questionnaires and standardized
interviews, to subgroup the ASD population and understand the
mechanisms involved may prove vital in future ASD studies,
including MRS studies.
Conclusion
We found a negative correlation between autism severity, as
measured by the ASSQ and GABA+/Cr in the ASD group, but
no GABA+ or GABA+/Cr level differences between ASD and TD
groups. The intricate balance between GABA and glutamate in
the brain in ASD is not completely understood. Recent evidence
even supports a deviant function of the GABA neurotransmitter
in children with ASDwith an excitatory rather than an inhibitory
effect indicating that absolute levels of GABA and glutamate may
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not reflect the E/I imbalance in the same way in ASD as in other
patient groups (Tyzio et al., 2014).
The present study clearly shows that autism severity must
be taken into account to elucidate the E/I hypothesis in autism.
Future studies with larger cohorts of ASD subjects in different
ages, severity and gender, and in different brain regions are
required to reveal the levels of GABA and glutamate and the
importance of the balance between them in relation to ASD
symptoms.
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